Valbiotis (ALVAL) Investor presentation summary

Company profile and mission

• Transitioned from R&D to marketing clinically tested natural health supplements targeting cardiometabolic imbalances and everyday health concerns.

• Focuses on cholesterol, metabolic syndrome, blood pressure, and metabolic liver disease.

• Four patented active substances with clinical efficacy against cardiometabolic disorders.

• Products are supported by robust clinical evidence and international scientific recognition.

• Holds ISO 9001 and CSR certifications, with a presence in France and a research chair in Canada.

Value proposition and scientific foundation

• Offers natural health supplements with high scientific value and no market equivalent.

• Backed by a prestigious scientific board and 11 clinical studies on efficacy and mechanisms.

• Collaborates with academic partners for innovation in metabolic health and immune defense.

• Products validated by international congresses and peer-reviewed publications.

• Everyday health range formulated with proven, safe ingredients.

Market trends and demand

• Rising demand for plant-based solutions addressing significant medical needs.

• Cardiometabolic imbalances affect hundreds of millions globally; high prevalence in France.

• French dietary supplement market valued at €2.7 billion, with pharmacies as key sales channels.

• Consumers prioritize natural origin, absence of additives, and expert advice over price.

• High rates of stress, sleep disorders, fatigue, and micronutrient deficiencies in France.